Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells

Nature Medicine

Volumn 2, Issue 5, 1996, Pages 574-577

  Friesen, Claudia ^a   Herr, Ingrid ^a   Krammer, Peter H ^b   Debatin, Klaus Michael ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOHEXIMIDE; CYCLOSPORIN A; DOXORUBICIN; FAS ANTIGEN; METHOTREXATE;

APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTIGENS, CD95; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CYCLOHEXIMIDE; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; FAS LIGAND PROTEIN; HUMANS; LEUKEMIA, T-CELL, ACUTE; MEMBRANE GLYCOPROTEINS; METHOTREXATE; PROTEIN SYNTHESIS INHIBITORS; TUMOR CELLS, CULTURED;

EID: 0029935682     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0596-574     Document Type: Article

References (25)

1. Barry, M.A., Behnke, C.A. & Eastman, A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem. Pharmacol. 40, 2353-2362 (1990).
2. Hickman, J.A. et al. Apoptosis and cancer chemotherapy. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 345 (1313), 319-325 (1994).
3. Trauth, B.C. et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245, 301-305 (1989).
4. Debatin, K.-M., Goldman, C.K., Bamford, R., Waldmann, T.A. & Krammer, P.H. Monoclonal antibody-mediated apoptosis in adult T cell leukemia. Lancet 335, 497-500 (1990).
5. Debatin, K.-M., Goldman, C.K., Waldmann, T.A. & Krammer, P.M. APO-1 induced apoptosis of leukemia cells from patients with adult T cell leukemia. Blood 81, 2972-2977 (1993).
6. Krammer, P.M. et al. The role of APO-1-mediated apoptosis in the immune system. Immunol. Rev. 142, 175-191 (1994).
7. Dhein, J., Walczak, H., Bäumler, C., Debatin, K.M. & Krammer, P.M. Autocrine T cell suicide mediated by APO-1 (Fas/CD95). Nature 373, 438-441 (1995).
8. Oehm, A. et al. Purification and molecular cloning of the APO-1 surface antigen, a member of the TNF/NGF receptor superfamily. J. Biol. Chem. 267, 10709-10715 (1992).
9. Itoh, N. et al. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66, 233-243 (1991).
10. Klas, C., Debatin, K.M., Jonker, R.R. & Krammer, P.H. Activation interferes with the apoptotic pathway in mature human T cells. Int. Immunol. 5, 625-630 (1993).
11. Kischkel, F.C. et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins (CAP) form a death-inducing signalling complex (DISC) with the receptor. EMBO J. (in the press).
12. Suda, T., Takahashi, S., Golstein, P. & Nagata, S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75, 1169-1178 (1993).
13. Tanaka, M., Suda, T., Takahashi, T. & Nagata, S. Expression of the functional soluble form of human Fas ligand in activated lymphocytes. EMBO J. 14, 1129-1135 (1995).
14. Mariani, S.M., Matiba, B., Bäumler, C. & Krammer, P.H. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur. J. Immunol. 25, 2303-2307 (1995).
15. Muller, C. et al. Cellular pharmacokinetics of doxorubicin in patients with chronic lymphocytic leukemia: Comparison of bolus administration and continuous infusion. Cancer Chemother. Pharmacol. 32, 379-384 (1993).
16. Cusack, B.J., Young, S.P., Driskell, J. & Olson, R.D. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer. Chemother. Pharmacol. 32, 53-58 (1993).
17. Skladanowski, A. & Konopa, J. Adriamycin and daunomycin induce programmed cell death (apoptosis) in tumor cells. Biochem. Pharmacol. 46, 375-382 (1993).
18. Thakkar, N.S. & Potten, C.S. Abrogation of adriamycin toxicity in vivo by cycloheximide. Biochem. Pharmacol. 43, 1683-1691 (1992).
19. Debatin, K.-M. & Krammer, P.H. Resistance to APO-1 (CD95) induced apoptosis in T-ALL is determined by a BCL-2 independent antiapoptotic program. Leukemia 9 (5), 815-820 (1995).
20. Bose, R. et al. Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signal. Cell 82, 405-414 (1995).
21. Cifone, M.G. et al. Apoptotic signaling through CD95 (Fas/APO-1) activates an acidic sphingomyelinase. Exp. Med. 177, 1547-1552 (1994)
22. Nicholson, D.W. et al. Identification and inhibition of ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376, 37-43 (1995).
23. Nicoletti, I., Migliorati, G., Pagliacci, M.C., Grignani, F. & Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immun. Methods 139, 271-279 (1991).
24. Carbonari, M. et al. Detection and characterization of apoptotic peripheral blood lymphocytes in human immunodeficiency virus-infection and cancer chemotherapy by a novel flow immunocytometric method. Blood 83, 1268-1277 (1994).
25. Herr, I. et al. Monitoring of CD95 (APO-1/FAS) ligand expression in human T cells by quantitative RT-PCR. Cell Death Diff. (in the press).